DGM
EPIX

Darwin Global Management’s ESSA Pharma EPIX Stock Holding History

Darwin Global Management’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-208,524
Closed -$5.96M – 14
2021
Q2 		$5.96M Buy
+208,524
New +$6.06M 0.96% 8

Other funds holding EPIX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Darwin Global Management's EPIX Position: Q3 2021 in Review

Darwin Global Management sold out of ESSA Pharma (EPIX) in Q3 2021, closing a stake of 208,524 shares — an estimated $5.96M sold.

Darwin Global Management first reported a position in EPIX in Q2 2021 and held it in 1 quarter. The position peaked at $5.96M in Q2 2021. 75 funds tracked by Wall St. Rank hold EPIX as of Q3 2021.

  • Darwin Global Management reported no remaining ESSA Pharma position as of Q3 2021 after selling out during the quarter.
  • Darwin Global Management sold 208,524 ESSA Pharma shares in Q3 2021, an estimated $5.96M.
  • Darwin Global Management first reported a position in ESSA Pharma in Q2 2021 and held it in 1 quarter.
  • Darwin Global Management's ESSA Pharma position peaked at $5.96M in Q2 2021.
  • 75 funds tracked by Wall St. Rank held ESSA Pharma as of Q3 2021.

Based on Darwin Global Management's 13F filing for Q3 2021, filed 15 Nov 2021.